# Exploratory Study to Investigate the Bioactivity, Ocular and Systemic Safety, Tolerability, and Pharmacokinetics Following Single and Multiple Intravitreal Administrations of KSI-301 in Subjects With wAMD, DME and RVO

> **NCT03790852** · PHASE1 · TERMINATED · sponsor: **Kodiak Sciences Inc** · enrollment: 121 (actual)

## Conditions studied

- Wet Age-related Macular Degeneration
- Retinal Vein Occlusion
- Diabetic Macular Edema

## Interventions

- **DRUG:** KSI-301

## Key facts

- **NCT ID:** NCT03790852
- **Lead sponsor:** Kodiak Sciences Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-12-26
- **Primary completion:** 2021-06-02
- **Final completion:** 2022-06-09
- **Target enrollment:** 121 (ACTUAL)
- **Why stopped:** All patients past planned primary endpoint; decision by Sponsor to wind down open-label follow-up activities.
- **Last updated:** 2024-03-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03790852

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03790852, "Exploratory Study to Investigate the Bioactivity, Ocular and Systemic Safety, Tolerability, and Pharmacokinetics Following Single and Multiple Intravitreal Administrations of KSI-301 in Subjects With wAMD, DME and RVO". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03790852. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*